Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard M. Stone, M.D.

Co-Author

This page shows the publications co-authored by Richard Stone and Philip Amrein.
Connection Strength

1.223
  1. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34.
    View in: PubMed
    Score: 0.157
  2. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4.
    View in: PubMed
    Score: 0.149
  3. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 01; 14(5):1446-54.
    View in: PubMed
    Score: 0.100
  4. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5.
    View in: PubMed
    Score: 0.058
  5. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.057
  6. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
    View in: PubMed
    Score: 0.055
  7. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
    View in: PubMed
    Score: 0.054
  8. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549.
    View in: PubMed
    Score: 0.053
  9. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
    View in: PubMed
    Score: 0.052
  10. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
    View in: PubMed
    Score: 0.049
  11. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
    View in: PubMed
    Score: 0.044
  12. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88.
    View in: PubMed
    Score: 0.044
  13. Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206.
    View in: PubMed
    Score: 0.043
  14. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
    View in: PubMed
    Score: 0.041
  15. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20.
    View in: PubMed
    Score: 0.036
  16. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013 May 24; 3:e117.
    View in: PubMed
    Score: 0.036
  17. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9.
    View in: PubMed
    Score: 0.035
  18. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012 Nov 29; 120(23):4649-52.
    View in: PubMed
    Score: 0.035
  19. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol. 2011 Jul; 86(7):625-7.
    View in: PubMed
    Score: 0.032
  20. Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011 Dec; 35(12):1611-5.
    View in: PubMed
    Score: 0.032
  21. Genomic alterations in myeloid neoplasms with novel, apparently balanced translocations. Cancer Genet. 2011 Feb; 204(2):68-76.
    View in: PubMed
    Score: 0.031
  22. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010 Dec; 85(12):956-7.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.